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ABSTRACT
Here, we present an updated version of CancerRe-
source, freely available without registration at http:
//bioinformatics.charite.de/care. With upcoming in-
formation on target expression and mutations in pa-
tients’ tumors, the need for systems supporting de-
cisions on individual therapy is growing. This knowl-
edge is based on numerous, experimentally vali-
dated drug-target interactions and supporting analy-
ses such as measuring changes in gene expression
using microarrays and HTS-efforts on cell lines. To
enable a better overview about similar drug-target
data and supporting information, a series of novel
information connections are established and made
available as described in the following. CancerRe-
source contains about 91 000 drug-target relations,
more than 2000 cancer cell lines and drug sensi-
tivity data for about 50 000 drugs. CancerResource
enables the capability of uploading external expres-
sion and mutation data and comparing them to the
database’s cell lines. Target genes and compounds
are projected onto cancer-related pathways to get a
better overview about how drug-target interactions
benefit the treatment of cancer. Features like cellu-
lar fingerprints comprising of mutations, expression
values and drug-sensitivity data can promote the un-
derstanding of genotype to drug sensitivity associ-
ations. Ultimately, these profiles can also be used
to determine the most effective drug treatment for
a cancer cell line most similar to a patient’s tumor
cells.
INTRODUCTION
According to the World Health Organisation cancer is one
of the most common causes for human death and has been
responsible for about 8.2million cases of deathworldwide in
the year 2012 (http://www.who.int/mediacentre/factsheets/
fs310/en/index312.html). To overcome difficulties in cancer
therapy and to develop new methods for cancer diagnosis
and treatment a huge amount of information is generated
in cancer research experiments like in drug-target assays,
high-throughput screenings on cancer cell lines or large-
scale cancer genomics projects including next-generation
sequencing studies (1–3).
In 2002 after the sequencing of the human genome, Hop-
kins and Groom established the term ‘druggable genome’
which comprises proteins that are known (or predicted) to
interact with drugs. In their study they reveal an amount of
3051 druggable targets (4). Since then, novel drug targets
have been identified that are relevant for cancer and which
could be bound by compounds to provoke an activating or
inhibiting molecular reaction, e.g. Superoxide dismutase 1
(SOD1). The overexpression of SOD1 results in lung cancer
cells’ growth and reduces apoptosis (5,6). It could be shown
that its enzymatic activity was inhibited by compounds in
lung cancer cells leading to growth inhibition of the cancer
cells suggesting it as a promising target for cancer therapy
(5).
Application ofmicroarray-based gene expression data for
cancer research is a broadly usedmethod for identifying sig-
nificant differentially expressed genes, compared to normal
tissue or other cancer tissues, or for profiling cancer signa-
tures, which can be associated with clinical outcome (7–9).
Microarray-based gene expression data can even be consid-
ered for identifying new therapeutic targets (10) or biomark-
ers for specific cancer types (11).
Nowadays, as a result of the establishment of next-
generation sequencing technologies and improved bioinfor-
matical evaluation a better understanding of the genomic
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foundation of cancer was achieved (12). Given that cancer is
a genetic disease, mutational characteristics of a cancer type
can vary from patient to patient even though if the patients
are affected by the apparently same cancer type. These ge-
nomic alterations might affect an anti-cancer drug’s efficacy
on the tumor and influence the clinical response. For in-
stance, the anti-cancer drug vemurafenib improves the over-
all survival rate of patients having the BRAF V600E muta-
tion (13). Consideration of genomic alterations in patients
is part of personalized medicine (14) and enables the op-
portunity of an improved cancer diagnosis and anti-cancer
therapy. Nevertheless, the analysis of these data and the
understanding of the genotype-phenotype relationship be-
tween genomic alterations and anti-cancer drug response
remains amajor challenge in cancer research (15). The Can-
cer Genome Atlas (TCGA) project focuses on generating
large-scale cancer genomics data sets which are stored by
the cBio Cancer Genomics Portal (cBioPortal) which also
provides further analysis tools (16).
To support, promote and gain a better insight into these
data the updated CancerResource database links gene ex-
pression values, gene mutations as well as drug-sensitivity
data to cell lines related to cancer. From the inclusion of
the data from the consortia ‘catalogue of somatic mutations
in cancer’ (CoSMIC) (17), ‘Cancer Cell Line Encyclopedia’
(CCLE) (18) and theCellMiner database (17) an explorative
data analysis is enabled helping to achieve a better under-
standing of specific drug response in cancer.
MATERIALS AND METHODS
Gene expression, mutation and drug sensitivity data
The cancer cell line expression, mutation and drug sensitiv-
ity data are provided by the CCLE (18), CoSMIC (19) and
CellMiner (17) websites, respectively.
All expression data are based on the Affymetrix HG-
U133 Plus 2.0 technology. In order to increase the compara-
bility of the expression data from three different sources, all
gene expression values were scaled and centered. To deter-
mine the similarity between cancer cell lines two similarity
measurements are used: first, the Pearson correlation dis-
tance; second, the percentage of a categorical classification
of genes based on the fold change between the genes of two
cancer cell lines.
Only somatic mutations were included in the similarity
analyses and germline variants such as single nucleotide
polymorphisms (SNPs) were excluded. The mutational sta-
tus of a gene was modeled boolean: gene is mutated, a one
was set; in case a wild-type was present, a zero was set. Simi-
larity of two cancer cell lines based on their mutations is the
amount of shared mutations, divided by all observed muta-
tions of both cancer cell lines. The similarity calculations
for mutations are accordingly based on the Tanimoto coef-
ficient calculation (20).
Drug sensitivity data provided by CellMiner were mea-
sured as growth inhibition (GI50). Data provided by CCLE
andCosMIC are given by IC50 andEC50 values. In case the
primary target of a drug is known, the consortia provide in-
formation about them. The activity data of the consortia
were scaled and centered to obtain a uniform format of the
data. The normalized data were used to create the cellular
fingerprint for every compound considering each consor-
tium separately when a compound occurred in more than
one consortium (21).
All cancer cell lines from one consortium have been com-
pared to each other. TheP-value calculations are based on a
normal distribution to the observed similarity for all cancer
cell lines of the same consortium. Cancer cell lines, whose
observed similarity differs from the expected percentage of
similarity in either direction with a P-value of less or equal
to 0.05 were counted as significantly similar or dissimilar.
Compound mapping and target identification
Protein targets for the CancerResource update have been
obtained from the ChEMBL database v. 19 (22). Those tar-
gets were filtered using the following criteria: First, all inter-
actions with an activity comment ‘inactive’, ‘inconclusive’
or ‘not active’ were removed. Second, only ‘homo sapiens’
was considered as organism and third, only protein target
types were extracted. The structures of the CancerResource
compounds and the ChEMBL compounds have been stan-
dardized using JChem (Instant Jchem version 14 10.27.0,
ChemAxon (http://www.chemaxon.com/)) for identifying
CancerResource compounds in ChEMBL. The standard-
ization steps included aromatization of the structures and
addition of explicit hydrogens. Furthermore, solvents and
salts were removed. Additionally, 3D structures were gen-
erated. For comparing the standardized CancerResource
compounds with the equally standardized ChEMBL com-
pounds InChiKeys were calculated and used for compound
identification. Furthermore, drug-target information from
CTD (23), TTD (24), PharmGKB (25) and DrugBank (26)
has been added to the database. The final data set includes
91 000 interactions whereat 11 000 compounds and 3400
targets are involved. Where available, 3D structures are
linked via Cancer3D (27).
Compound similarity
The structural similarity search for uploaded structures is
based on extended-connectivity fingerprints (ECFP). For
the computation of the circular topological fingerprints the
diameter, which defines the circular neighborhood consid-
ered for each atom, was set to 4 (ECFP4). The calcula-
tion of these fingerprints was performed by the cheminfor-
matics toolkit of ChemAxon (JChem compr (14.10.20.0),
201n (2014), ChemAxon (http://www.chemaxon.com/)). All
other parameters provided by ChemAxon were used in de-
fault configuration. To determine the similarity between the
compounds stored in the database, the Tanimoto coefficient
is calculated. The Tanimoto calculation on the website is
performed by MyChem (http://mychem.sourceforge.net/).
Pathways
To achieve a better understanding of drug-target interac-
tions at molecular level, KEGG (signaling) pathways (28)
were analyzed according to their relevance in cancer emer-
gence and cancer development. This set comprises cancer-
specific pathways, pathways related to cell-cycle regulation,
replication, immune response and drug metabolism. Path-
way maps are dynamically retrieved via Web service from
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Figure 1. Overview of the functionality of CancerResource illustrating input variants, search options and result variants of the database.
KEGG facultative with highlighted expression data if gene
expression is computed online before.
Server, database and system requirements
CancerResource is based on a relational MySQL database
(http://www.mysql.com/). The database is normalized to
the third normal form, for which large tables were split
into smaller ones to minimize redundancy and dependency.
The website of CancerResource is build using PHP (http:
//www.php.net/), JavaScript (http://www.java.com/), Ajax
and web access is enabled via an Apache HTTP Server
(http://apache.org/). For optimal usage we strongly recom-
mend the latest version of Mozilla Firefox, Google Chrome
or Safari browser and Internet Explorer, in descending or-
der, with JavaScript option enabled.
RESULTS
CancerResource is comprised of about 50 000 com-
pounds with detailed information like synonyms, struc-
ture identifier (SMILES, InChiKeys) as well as hydrogen
bonds, molecular weight and logP values. Additionally,
the database provides links to PubChem. Furthermore,
about 3400 protein targets could be identified for the com-
pounds stored in the database. This results in about 91 000
compound-target interactions. By integrating CCLE and
CoSMIC into CancerResource the total number of cancer
cell lines now exceeds 2000. Mutation information for 19
834 genes, expression values for 23 016 genes and about 872
658 mutations from the consortia that were collected and
included and are now available in CancerResource.
The CancerResource website provides different possibil-
ities for the user to start using the database. Regardless of
how the user begins a search, all results are interconnected
via different joining’s. An overview of the multiple search
forms is displayed in Figure 1. These search options are de-
scribed in more detail in the following sections.
Compound search for alternative, most effective drugs
CancerResource can easily be searched for compounds. For
this purpose, two search categories are available. On the one
hand, the database can be browsed by the compound’s prop-
erties like name,molecular weight, number of atoms or logP
value. On the other hand, a connection to PubChem is es-
tablished by which the user can search by compound name
or SMILES. If no structures could be found via PubChem, a
structure can be drawn by themolecule sketching tool. If the
structure is available in the database detailed information
about physicochemical properties, drug-target interactions,
pathway information and an activity profile to all available
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cancer cell lines are presented. Furthermore, the ten most
similar compounds are listed for which detailed informa-
tion can be displayed interactively.
Gene/target search
Targets can be found via different gene identifiers. Extended
information about the target is displayed including expres-
sion profiles and drugs interacting with the target. Informa-
tion about cancer cell lines, where the gene is mutated is also
provided (mutation profile). If target-pathway mapping is
possible, cancer relevant pathways are displayed.
Cell line/expression profile search
To searchCancerResource formRNAexpression profiles of
genes of interest different variants are prepared for the user.
Besides searching for mRNA expression profiles of several
selected genes between different cancer cell lines, the user
can also upload an external expression profile to compare
it to the database. As a result, the most similar cancer cell
lines are presented to the user for which again detailed in-
formation can be displayed interactively. The results are ac-
cessible for at least one month by accessing the data via a
bookmark of the web page.
A direct search for a specific cancer cell line or tissue type
is also provided on the website. The results also embrace
the most effective drugs against the cancer cell line as well
as a tabular presentation of the similarity to other cancer
cell lines based on a compound’s activity-, mutation- and
expression-fingerprint, respectively.
Mutation profile search
Searching for mutation profiles is enabled on the website.
On the one hand, the user can search for gene mutations
that occur in cancer-relevant genes. On the other hand, the
user can search for gene mutations that occur in a cancer
cell line of interest. Additionally, a tissue specific search is
included. Furthermore, the opportunity to upload a muta-
tion profile of user-provided tumor cells was implemented
to compare them to well-characterized cancer cell lines and
to identify the most similar cancer cell line based on muta-
tions.
Pathway search
To provide a detailed insight into cancer relevant pathways
a search by pathway names is provided. For this purpose
pathway maps were extracted from the KEGG database.
All targets of those maps for which compound-target in-
teractions are available in CancerResource are highlighted.
A mouse-over for those targets is made available displaying
the binding compounds in a pop-up. Based on the chosen
option, all cancer cell lines with certain mutated gene(s) or
all mutations occurring in one specific cancer cell line are
displayed.
From this site interactive browsing to detailed informa-
tion, to cancer cell lines or genes is available to collect fur-
ther information like most effective drugs or to compare the
cancer cell line to others.
Similarity comparison
The user interface provides four ways to measure similarity
of cancer cell lines. Similarity is calculated by the activity
profile of compounds for two cancer cell lines, a Pearson
distance correlation of expression values of genes, percent-
age similarity of known mutations of genes and a similarity
measurement of a categorical classification of genes based
on the fold changes between the genes of two cancer cell
lines. Additionally, two options are provided to the user to
calculate the similarity of own data to cancer cell line data
from the three consortia. The results are presented in heat
maps and differentially expressed genes are displayed.
Comparison to other databases
Adetailed comparison to the original CancerResource (29),
canSAR (30) and CancerDR (31) is represented in Table 1.
The upload of external mutation data and expression values
for cell lines or patient data to find the most similar can-
cer cell lines in the database is considered as a unique fea-
ture of the new version of CancerResource. Another feature
of CancerResource is the mapping and annotation of can-
cer relevant protein targets to KEGG pathways. An addi-
tional extension of the updated CancerResource compared
to other databases is the integration of mutation, expres-
sion and drug sensitivity data from the CCLE, CoSMIC
and CellMiner consortia and to provide additionally a dy-
namic drug sensitivity comparison for external mutation or
expression data. By this tool the user is enabled to create
own hypotheses, which might possibly not have been devel-
oped by taking only one of the consortia into account.
USE CASES
Upload of own gene expression or mutation data to find an
alternative, most effective drug for a tumor similar to a cancer
cell line
CancerResource can be used to identify the most similar
cancer cell line of an external tissue sample by using ei-
ther gene expression or mutation data. Therefore, normal-
ized data fromHumanGenomeU133AorHumanGenome
U133 Plus 2.0 microarray chips from Affymetrix can be
queried either by Affymetrix probe set IDs or HGNC gene
symbols. Based on the most similar cancer cell line the most
effective drug for the external tissue is determined. To iden-
tify the most similar cancer cell line by applying gene ex-
pression data a Pearson correlation distance and addition-
ally the percentage of the categorical classification of genes
based on the fold change between the uploaded data and all
cancer cell lines stored in CancerResource are calculated.
Interconnections to most effected genes in the resulting cell
line and additional similar cell lines are displayed as heat-
maps. Alternatively, gene identifiers of mutated genes of the
external tissue can be used to query the database for the
most similar cancer cell line of the respective consortia. The
next step gives an overview of the most effective drugs for
the determined similar cancer cell line of the input data. A
visualization of this use case is shown in Figure 2.
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Table 1. Comparison of the updated CancerResource database with the original CancerResource, canSAR and CancerDR databases
Update Cancer
Resource Cancer Resource (29) canSAR (30) CancerDR (31)
Expression, Mutation and Drug
Sensitivity
All Expression and drug
sensitivity
All Only mutation and drug
sensitivity
Cellminer, CCLE and CoSMIC All Only CellMiner All Only CCLE and CoSMIC
Dynamic Drug Sensitivity Comparison Yes Yes No No
Pathways Yes Yes Yes Overview
Cell lines 2037 60 11 000 952
Drugs with Drug Sensitivity Data 48 404 ≈40 000 16 000 148
Mutated Genes 19 799 No Yes Yes
No. of Genes 23 016 11 964 3466 studies
Protein Targets 3387 2392 All 116
Integrated Similarity Measurements Yes Expression No No
Upload of external mutation data or
expression values
Yes Only expression No No
Figure 2. Use case––upload of external mutation or mRNA expression data to find similar cancer cell lines and alternative/most effective drugs for the
external sample. Expression andmutation profiles for selected genes are available and in addition amapping of genes to cancer relevant pathways is enabled.
Cancer cell line compound response
Almost 50 000 compounds that are stored in CancerRe-
source have been screened against about 2000 cancer cell
lines to determine their drug sensitivity. These data have
been made available in the database. To identify which
cancer cell line has a high or low sensitivity towards a
compound, a similarity search is implemented within the
database comparing a query compound to all compounds
of CancerResource. If the query compound is found to be
identical to a database compound, the user will directly
be passed to the compound’s details page. Otherwise, the
ten most similar compounds found in the database are dis-
played. The ‘similar property principle’ (32) forms the bases
for the similarity search and states that similar compounds
might have similar properties in this case similar cancer cell
line compound responses. By choosing one of the similar
compounds the user will be forwarded to the compound’s
details page. On the details page of the identical or simi-
lar compound(s) the cellular fingerprint of the compound
is displayed showing high and low responding cancer cell
lines.
DISCUSSION AND OUTLOOK
Cancers, even from the same tissue, are extremely divergent
in terms of gene alterations and therapy resistance. There-
fore, individual therapy is required and will be made possi-
ble by understanding the entirety of single nucleotide poly-
morphisms (SNPs), complete or partial gene deletions, copy
number variations, gene aberrations, gene fusions etc. All
those issues may cause substantial dysfunctions or defected
genes that have influence on gene regulation. The hetero-
geneity of tumors (33) and their reaction on chemotherapy
(or other treatments) causes a further challenge, which will
be addressed in a new release of CancerResource. Recently,
tumor stratification not only based on somatic mutations
but also on epigenetic changes like methylation has been
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proven successful (34) and should become part of a future
update to further support the development of personalized
therapies. The data content of CancerResource is going to
be updated in a yearly pattern based on the regular updates
of the source data, which occur to be in a time period be-
tween three months and two years.
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